Positive Interim Clinical Results for VT-1161 to be Presented at the Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting

-Data from Planned Interim Analysis of Phase 2b Trial in Recurrent
Vulvovaginal Candidiasis (RVVC) Demonstrate Potential Significant
Advantages Over Current Treatment Paradigms-

Pharmaceuticals, Inc.
today announced that data from a planned
interim analysis of REVIVE, a Phase 2b clinical trial of oral VT-1161 in
recurrent vulvovaginal candidiasis (RVVC), will be presented by Dr. Jack
Sobel, Dean, Department of Medicine, Wayne State University, at the
Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) annual
meeting, to be held August 11-13, in Annapolis, Maryland. VT-1161, the
company’s lead product candidate, is a highly potent and selective
inhibitor of fungal CYP51.

“RVVC is estimated to occur in 5% to 8% of women during their
child-bearing years,” stated Dr. Sobel. “There are no approved therapies
for RVVC and effectively treating the millions of women suffering from
this condition remains a significant clinical challenge. Having an
approved therapy to treat RVVC would be very exciting and I am pleased
to be working with Viamet in the development of VT-1161 for this

In preclinical studies, VT-1161 demonstrated highly potent activity
against a broad range of Candida species, the causative fungal
pathogens of RVVC. A planned interim analysis of the REVIVE study was
conducted when approximately 100 patients had completed the first 24
weeks of the trial. Positive efficacy and safety data from the interim
analysis and data from preclinical studies of VT-1161 will be presented
by Dr. Sobel at IDSOG on Saturday, August 13, beginning at 8:55 a.m.
(EST) in the Capitol D Room of the Westin Annapolis Hotel.

“We are pleased to collaborate with Dr. Sobel and our other REVIVE
investigators to address this significant unmet medical need,” said Dr.
Robert Schotzinger, President and CEO of Viamet. “Because of its
outstanding potency, broad therapeutic index and long half-life, we
believe VT-1161 may be a highly effective therapy for RVVC and become
the first antifungal agent approved for this very common and problematic

About VT-1161
VT-1161 is a potent and selective,
orally-administered inhibitor of fungal CYP51 currently in Phase 2b
clinical trials for the treatment of onychomycosis, or fungal nail
infection, (the RENOVATE study) and recurrent vulvovaginal candidiasis
(the REVIVE study). VT-1161 blocks the production of ergosterol, an
essential component of the fungal cell membrane. In preclinical studies,
VT-1161 has demonstrated broad-spectrum activity against fungal
pathogens, including those species that cause onychomycosis and
recurrent vulvovaginal candidiasis. Given the clinical and pre-clinical
profile of VT-1161, Viamet believes that it may minimize the safety
liabilities that limit the use of current oral antifungal therapies,
such as liver toxicity, drug-drug interactions and potential for birth
defects. Viamet previously reported robust interim efficacy and safety
data from the RENOVATE study and a favorable safety and efficacy profile
in a Phase 2a proof-of-concept study in the treatment of acute
vulvovaginal candidiasis (AVVC). Top-line final results for both the
RENOVATE and REVIVE studies are anticipated in the fourth quarter of

About the REVIVE Study
REVIVE (REcurrent
Vulvovaginal Candidiasis Inhibition:
An Oral VT-1161 Tablet Evaluation)
is a randomized, double-blind, placebo-controlled, 48-week clinical
study of VT-1161 in subjects with recurrent vulvovaginal candidiasis
(RVVC). RVVC was defined as three or more episodes of acute vulvovaginal
candidiasis, or AVVC (commonly referred to as a vaginal yeast
infection), in a 12-month period. The trial is evaluating two dose
levels of VT-1161 administered once weekly for either 11 or 23 weeks,
following an initial one-week daily loading dose period. At baseline in
the REVIVE study, the mean number of patient-reported AVVC episodes per
patient in the prior 12 months ranged from 4.5 to 6.0 across the study
arms. The trial has enrolled 215 patients at 32 sites throughout the
U.S. The primary efficacy endpoint is the proportion of subjects with
one or more culture-verified AVVC episodes through 48 weeks.

About Viamet (www.viamet.com)
discovers and develops breakthrough therapies based on our leadership in
metalloenzyme chemistry and biology. Our clinical portfolio includes
novel agents to treat both chronic and life threatening fungal
infections. We also leverage our metalloenzyme expertise in other
therapeutic areas including oncology and orphan diseases. Focusing on
the needs of patients and clinicians, we design our drug candidates to
achieve superior efficacy and safety profiles compared to currently
marketed drugs.

This press release includes forward-looking statements. Actual
results may vary materially from these statements. There are many
important risks affecting Viamet’s business, including that clinical
trials may not be commenced, or if commenced, may not be successful,
regulatory approvals may not be obtained and approved products, if any,
may not achieve commercial success. The Viamet group of companies
includes Viamet Pharmaceuticals Holdings, LLC and its operating
subsidiaries, Viamet Pharmaceuticals, Inc., VPS-2, Inc. and VPS-3, Inc.
The Viamet group of companies are based in the Research Triangle Park
region of North Carolina, USA.


Media Contact:
MacDougal Biomedical Communications
McCarthy Atkinson, +1 812-454-6257
Main: +1 781-235-3060